Prognostic values of the inhibitor of DNA‑binding family members in breast cancer

Zhou,Xiao‑Ling; Zeng,De; Ye,Yan‑Hong; Sun,Shu‑Ming; Lu,Xiao‑Feng; Liang,Wei‑Quan; Chen,Chun‑Fa; Lin,Hao‑Yu

doi:10.3892/or.2018.6589

Prognostic values of the inhibitor of DNA‑binding family members in breast cancer

Authors:
- Xiao‑Ling Zhou
- De Zeng
- Yan‑Hong Ye
- Shu‑Ming Sun
- Xiao‑Feng Lu
- Wei‑Quan Liang
- Chun‑Fa Chen
- Hao‑Yu Lin
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515000, P.R. China, Department of Medical Oncology, The Cancer Hospital of Shantou University Medical College, Shantou, Guangdong 515000, P.R. China, Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515000, P.R. China
Published online on: July 23, 2018 https://doi.org/10.3892/or.2018.6589
Pages: 1897-1906
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The inhibitor of DNA‑binding (ID) proteins are dominant‑negative modulators of transcription factors with basic helix‑loop‑helix (bHLH) structures, which control a variety of genes in cell cycle regulation. An increasing volume of evidence has demonstrated that the deregulated expression of IDs in several types of malignancy, including breast carcinoma, has been proven to serve crucial regulatory functions in tumorigenesis and the development of breast cancer (BC). The present study evaluated the prognostic values of the ID family members by investigating a set of publicly accessible databases, including Oncomine, bc‑GenExMiner, Kaplan‑Meier plotter and the Human Protein Atlas. The results demonstrated that mRNA levels of distinct IDs exhibited diverse profiles between BC and normal counterparts. The mRNA expression level of ID2 was significantly higher in breast cancer than normal tissues, while the mRNA expression levels of ID1, ID3 and ID4 were significantly lower in breast cancer tissues than in normal tissues. Furthermore, higher mRNA expression levels of ID1 and ID4 were associated with subgroups with lower pathological grades and fewer lymph node metastases. Survival analysis revealed that elevated mRNA levels of ID1 and ID4 predicted an improved survival in all patients with BC. Increased ID1 mRNA levels were associated with higher relapse‑free survival rates in all patients with BC, particularly in those with ER positive and Luminal A subtype tumors. Increased ID4 mRNA expression predicted longer survival times in all patients with BC, particularly in those with hormone receptor‑positive tumors or those treated with endocrine therapy. These results indicated that IDs are essential prognostic indicators in BC. Future studies on the effect of IDs on the pathogenesis and development of BC are warranted.

View Figures

View References

1	Yokota Y and Mori S: Role of Id family proteins in growth control. J Cell Physiol. 190:21–28. 2002. View Article : Google Scholar : PubMed/NCBI
2	Patel D, Morton DJ, Carey J, Havrda MC and Chaudhary J: Inhibitor of differentiation 4 (ID4): From development to cancer. Biochim Biophys Acta. 1855:92–103. 2015.PubMed/NCBI
3	Kamalian L, Gosney JR, Forootan SS, Foster CS, Bao ZZ, Beesley C and Ke Y: Increased expression of Id family proteins in small cell lung cancer and its prognostic significance. Clin Cancer Res. 14:2318–2325. 2008. View Article : Google Scholar : PubMed/NCBI
4	Cruz-Rodriguez N, Combita AL, Enciso LJ, Quijano SM, Pinzon PL, Lozano OC, Castillo JS, Li L, Bareño J, Cardozo C, et al: High expression of ID family and IGJ genes signature as predictor of low induction treatment response and worst survival in adult Hispanic patients with B-acute lymphoblastic leukemia. J Exp Clin Cancer Res. 35:642016. View Article : Google Scholar : PubMed/NCBI
5	Perk J, Iavarone A and Benezra R: Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer. 5:603–614. 2005. View Article : Google Scholar : PubMed/NCBI
6	O'Brien CA, Kreso A, Ryan P, Hermans KG, Gibson L, Wang Y, Tsatsanis A, Gallinger S and Dick JE: ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21. Cancer Cell. 21:777–792. 2012. View Article : Google Scholar : PubMed/NCBI
7	Ren Y, Cheung HW, von Maltzhan G, Agrawal A, Cowley GS, Weir BA, Boehm JS, Tamayo P, Karst AM, Liu JF, et al: Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med. 4:147ra1122012. View Article : Google Scholar : PubMed/NCBI
8	Zhao TF, Jia HZ, Zhang ZZ, Zhao XS, Zou YF, Zhang W, Wan J and Chen XF: LncRNA H19 regulates ID2 expression through competitive binding to hsa-miR-19a/b in acute myelocytic leukemia. Mol Med Rep. 16:3687–3693. 2017. View Article : Google Scholar : PubMed/NCBI
9	Korang-Yeboah M, Patel D, Morton D, Sharma P, Gorantla Y, Joshi J, Nagappan P, Pallaniappan R and Chaudhary J: Intra-tumoral delivery of functional ID4 protein via PCL/maltodextrin nano-particle inhibits prostate cancer growth. Oncotarget. 7:68072–68085. 2016. View Article : Google Scholar : PubMed/NCBI
10	Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL and Massagué J: Genes that mediate breast cancer metastasis to lung. Nature. 436:518–524. 2005. View Article : Google Scholar : PubMed/NCBI
11	Gupta GP, Perk J, Acharyya S, de Candia P, Mittal V, Todorova-Manova K, Gerald WL, Brogi E, Benezra R and Massagué J: ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci USA. 104:19506–19511. 2007. View Article : Google Scholar : PubMed/NCBI
12	Lasorella A, Benezra R and Iavarone A: The ID proteins: Master regulators of cancer stem cells and tumour aggressiveness. Nat Rev Cancer. 14:77–91. 2014. View Article : Google Scholar : PubMed/NCBI
13	Sikder HA, Devlin MK, Dunlap S, Ryu B and Alani RM: Id proteins in cell growth and tumorigenesis. Cancer Cell. 3:525–530. 2003. View Article : Google Scholar : PubMed/NCBI
14	Sun XH, Copeland NG, Jenkins NA and Baltimore D: Id proteins Id1 and Id2 selectively inhibit DNA binding by one class of helix-loop-helix proteins. Mol Cell Biol. 11:5603–5611. 1991. View Article : Google Scholar : PubMed/NCBI
15	Rollin J, Bléchet C, Régina S, Tenenhaus A, Guyétant S and Gidrol X: The intracellular localization of ID2 expression has a predictive value in non small cell lung cancer. PLoS One. 4:e41582009. View Article : Google Scholar : PubMed/NCBI
16	Chen XS, Zhang YH, Cai QY and Yao ZX: ID2: A negative transcription factor regulating oligodendroglia differentiation. J Neurosci Res. 90:925–932. 2012. View Article : Google Scholar : PubMed/NCBI
17	Kleeff J, Ishiwata T, Friess H, Buchler MW, Israel MA and Korc M: The helix-loop-helix protein Id2 is overexpressed in human pancreatic cancer. Cancer Res. 58:3769–3772. 1998.PubMed/NCBI
18	Li K, Yao L, Chen L, Cao ZG, Yu SJ, Kuang XY, Hu X and Shao ZM: ID2 predicts poor prognosis in breast cancer, especially in triple-negative breast cancer, and inhibits E-cadherin expression. Onco Targets Ther. 7:1083–1094. 2014.PubMed/NCBI
19	Itahana Y, Singh J, Sumida T, Coppe JP, Parrinello S, Bennington JL and Desprez PY: Role of Id-2 in the maintenance of a differentiated and noninvasive phenotype in breast cancer cells. Cancer Res. 63:7098–7105. 2003.PubMed/NCBI
20	Stighall M, Manetopoulos C, Axelson H and Landberg G: High ID2 protein expression correlates with a favourable prognosis in patients with primary breast cancer and reduces cellular invasiveness of breast cancer cells. Int J Cancer. 115:403–411. 2005. View Article : Google Scholar : PubMed/NCBI
21	Kowanetz M, Valcourt U, Bergström R, Heldin CH and Moustakas A: Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein. Mol Cell Biol. 24:4241–4254. 2004. View Article : Google Scholar : PubMed/NCBI
22	Wen YH, Ho A, Patil S, Akram M, Catalano J, Eaton A, Norton L, Benezra R and Brogi E: Id4 protein is highly expressed in triple-negative breast carcinomas: Possible implications for BRCA1 downregulation. Breast Cancer Res Treat. 135:93–102. 2012. View Article : Google Scholar : PubMed/NCBI
23	Thike AA, Tan PH, Ikeda M and Iqbal J: Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival. Histopathology. 68:702–712. 2016. View Article : Google Scholar : PubMed/NCBI
24	Lin HY, Zeng Liang YK, Wei XL and Chen CF: GATA3 and TRPS1 are distinct biomarkers and prognostic factors in breast cancer: Database mining for GATA family members in malignancies. Oncotarget. 8:34750–34761. 2017.PubMed/NCBI
25	Jezequel P, Frenel JS, Campion L, Guérin-Charbonnel C, Gouraud W, Ricolleau G and Campone M: bc-GenExMiner 3.0: New mining module computes breast cancer gene expression correlation analyses. Database. 2013:bas0602013. View Article : Google Scholar : PubMed/NCBI
26	Jezequel P, Campone M, Gouraud W, Guérin-Charbonnel C, Leux C, Ricolleau G and Campion L: bc-GenExMiner: An easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat. 131:765–775. 2012. View Article : Google Scholar : PubMed/NCBI
27	Thul PJ, Akesson L, Wiking M, Mahdessian D, Geladaki A, Blal Ait H, Alm T, Asplund A, Björk L, Breckels LM, et al: A subcellular map of the human proteome. Science. 356:pii: eaal3321. 2017. View Article : Google Scholar : PubMed/NCBI
28	Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
29	Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q and Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
30	Curtit E, Pivot X, Henriques J, Paget-Bailly S, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, et al: Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: No correlation with clinico-pathological characteristics and outcomes. Breast Cancer Res. 19:982017. View Article : Google Scholar : PubMed/NCBI
31	Fragomeni SM, Sciallis A and Jeruss JS: Molecular subtypes and local-regional control of breast cancer. Surg Oncol Clin N Am. 27:95–120. 2018. View Article : Google Scholar : PubMed/NCBI
32	Pawlik TM: Innovation in the diagnosis and management of breast cancer. Surg Oncol Clin N Am. 27:xiii–xiv. 2018. View Article : Google Scholar
33	Murad JM, Place CS, Ran C, Hekmatyar SK, Watson NP, Kauppinen RA and Israel MA: Inhibitor of DNA binding 4 (ID4) regulation of adipocyte differentiation and adipose tissue formation in mice. J Biol Chem. 285:24164–24173. 2010. View Article : Google Scholar : PubMed/NCBI
34	Yang HY, Liu HL, Ke J, Wu H, Zhu H, Liu JR, Liu LX and Jiang HC: Expression and prognostic value of Id protein family in human breast carcinoma. Oncol Rep. 23:321–328. 2010.PubMed/NCBI
35	Wazir U, Jiang WG, Sharma AK, Newbold RF and Mokbel K: The mRNA expression of inhibitors of DNA binding-1 and −2 is associated with advanced tumour stage and adverse clinical outcome in human breast cancer. Anticancer Res. 33:2179–2183. 2013.PubMed/NCBI
36	Umetani N, Mori T, Koyanagi K, Shinozaki M, Kim J, Giuliano AE and Hoon DS: Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene. 24:4721–4727. 2005. View Article : Google Scholar : PubMed/NCBI
37	Li B, Tsao SW, Li YY, Wang X, Ling MT, Wong YC, He QY and Cheung AL: Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway. Int J Cancer. 125:2576–2585. 2009. View Article : Google Scholar : PubMed/NCBI
38	Gumireddy K, Li A, Kossenkov AV, Cai KQ, Liu Q, Yan J, Xu H, Showe L, Zhang L and Huang Q: ID1 promotes breast cancer metastasis by S100A9 regulation. Mol Cancer Res. 12:1334–1343. 2014. View Article : Google Scholar : PubMed/NCBI
39	Cheng YJ, Lee YC, Chiu WC, Tsai JW, Su YH, Hung AC, Chang PC, Huang CJ, Chai CY and Yuan SS: High Id1 expression, a generally negative prognostic factor, paradoxically predicts a favorable prognosis for adjuvant paclitaxel plus cisplatin therapy in surgically treated lung cancer patients. Oncotarget. 5:11564–11575. 2014. View Article : Google Scholar : PubMed/NCBI
40	Zhang Y, Zhang B, Fang J and Cao X: Hypomethylation of DNA-binding inhibitor 4 serves as a potential biomarker in distinguishing acquired tamoxifen-refractory breast cancer. Int J Clin Exp Pathol. 8:9500–9505. 2015.PubMed/NCBI
41	Patel D, Knowell AE, Korang-Yeboah M, Sharma P, Joshi J, Glymph S, Chinaranagari S, Nagappan P, Palaniappan R, Bowen NJ and Chaudhary J: Inhibitor of differentiation 4 (ID4) inactivation promotes de novo steroidogenesis and castration-resistant prostate cancer. Mol Endocrinol. 28:1239–1253. 2014. View Article : Google Scholar : PubMed/NCBI
42	Sharma P, Chinaranagari S and Chaudhary J: Inhibitor of differentiation 4 (ID4) acts as an inhibitor of ID-1, −2 and −3 and promotes basic helix loop helix (bHLH) E47 DNA binding and transcriptional activity. Biochimie. 112:139–150. 2015. View Article : Google Scholar : PubMed/NCBI